Revvity, Inc. (RVTY)
| Market Cap | 17.24B +61.5% |
| Revenue (ttm) | 2.94B +4.6% |
| Net Income | 253.20M +6.6% |
| EPS | 2.26 +13.5% |
| Shares Out | 111.64M |
| PE Ratio | 68.31 |
| Forward PE | 26.60 |
| Dividend | $0.28 (0.18%) |
| Ex-Dividend Date | Jan 22, 2027 |
| Volume | 1,306,669 |
| Open | 160.17 |
| Previous Close | 157.02 |
| Day's Range | 151.06 - 160.59 |
| 52-Week Range | 81.22 - 171.74 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 171.07 (+10.8%) |
| Earnings Date | Nov 3, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, i... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $171.07, which is an increase of 10.80% from the latest price.
News
Revvity Transcript: Investor Day 2026
Long-term targets call for 6%-8% organic growth, 75 bps of annual margin expansion, and double-digit EPS growth. AI, Signals product launches, and diagnostic expansion offer upside beyond the base plan.
Revvity Slides: FY 2026
Revvity has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 13, 2026.
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today will host its 2026 Investor Day, highlighting the Company's differentiated portfolio of Life Sciences and Diagnostics solutions, as we...
Revvity price target raised to $185 from $175 at TD Cowen
TD Cowen raised the firm’s price target on Revvity (RVTY) to $185 from $175 and keeps a Buy rating on the shares. The firm updated its model following solid Q3…
Revvity price target raised to $185 from $165 at BofA
BofA raised the firm’s price target on Revvity (RVTY) to $185 from $165 and keeps a Neutral rating on the shares.
Revvity price target raised to $172 from $135 at RBC Capital
RBC Capital raised the firm’s price target on Revvity (RVTY) to $172 from $135 and keeps a Sector Perform rating on the shares after its Q3 earnings beat and guidance…
Revvity price target raised to $160 from $155 at JPMorgan
JPMorgan raised the firm’s price target on Revvity (RVTY) to $160 from $155 and keeps a Neutral rating on the shares.
Revvity price target raised to $177 from $110 at Stifel
Stifel raised the firm’s price target on Revvity (RVTY) to $177 from $110 and keeps a Hold rating on the shares.
Revvity price target raised to $190 from $164 at Baird
Baird raised the firm’s price target on Revvity (RVTY) to $190 from $164 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Revvity price target raised to $175 from $160 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Revvity (RVTY) to $175 from $160 and keeps an Equal Weight rating on the shares.
Revvity price target raised to $180 from $165 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Revvity (RVTY) to $180 from $165 and keeps an Outperform rating on the shares. Revvity posted “a good print,”…
Revvity Earnings Call Transcript: Q3 2026
Q3 pro forma organic growth reached 7%, led by Life Sciences, with 29.4% adjusted operating margin and $1.37 adjusted EPS. FY organic growth guidance rose to ~5%, supported by improving end markets, early AI demand, and operational efficiencies.
Revvity Slides: Q3 2026
Revvity has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Revvity Earnings release: Q3 2026
Revvity released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Revvity Quarterly report: Q3 2026
Revvity has published its Q3 2026 quarterly earnings report on November 3, 2026.
Revvity reports Q3 adjusted EPS $1.37, consensus $1.30
Reports Q3 revenue $729M, consensus $694.74M. “Our exceptional third quarter performance demonstrates the momentum building across Revvity (RVTY), as broad-based growth and strong execution drove resu...
Revvity sees FY26 adjusted EPS $5.40-$5.45, consensus $5.35
Sees FY26 revenue approximately $2.86B, consensus $2.85B.
Revvity Announces Financial Results for the Third Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026. The Company reported GAAP earnings per share from continuing ...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Febru...
Citrini bullish on Charles River, Revvity after testing Claude, Bloomberg says
After testing Anthropic’s Claude Science, Citrini Research believes life sciences companies will benefit from a surge in AI-driven drug discovery, Georgie McKay and Angel Adegbesan of Bloomberg report...
Revvity announces Revvity Signals Software launch of Signals LabGistics
Revvity (RVTY) announced that its Revvity Signals Software business is launching the Signals LabGistics solution, an AI-first, scientific workflow orchestration solution designed to connect and coordi...
Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orches...
Revvity price target raised to $175 from $130 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Revvity (RVTY) to $175 from $130 and keeps a Buy rating on the shares. The firm adjusted targets in…
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 20...